"PD-L1 is clinically useful but imperfect," expert says ...

RNA-based testing improved identification of actionable MET exon 14 skipping alterations in lung cancer, supporting more ...

According to MarketsandMarkets™, the Cancer Tumor Profiling Market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion ...

Experimentation on patient-derived organoids could hasten more personalized treatments for breast cancer, including the ...

(Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation ...

According to MarketsandMarkets, the Cancer Tumor Profiling Market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in ...

Blood‑and‑tissue‑derived Biomarkers Serve as the Key to Lung‑cancer Precision‑medicine Breakthrough HUSTON, TX, UNITED STATES, August 10, 2026 /EINPresswire.com/ — Breaking the Curse of Lung Cancer: ...

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid ...

Precision medicine uses genomics and data analysis to tailor diagnosis and treatment, transforming cancer care outcomes.

Worldwide and in the United States, lung cancer is the leading cause of cancer and cancer death, and in the US, about 15% of lung cancer cases arise in people who have never smoked. Long term exposure ...

Key opportunities include oncolytic viruses, CAR-T and bispecific antibodies, combination regimens, biomarker-led care, hematologic cancers, expanded solid-tumor indications, outcome-based ...

UW researcher Irene Ong uses AI and electronic health records to identify early warning signs of ovarian cancer, aiming to ...